Adcendo ApS

Nordre Fasanvej 215
2000 Frederiksberg
CVR DK38780093

For all inquiries, please contact Adcendo via e-mail:

For media inquiries:

Optimum Strategic Communications
Mary Clark, Zoe Bolt, Elena Bates
Tel: +44 (0) 203 882 9621

Investor Contact:

Michael Pehl, CEO
Tel: +45 31541824

About Adcendo

Adcendo was founded in 2017 as a spin-out from The University of Copenhagen and Rigshospitalet. The scientific founders, Niels Behrendt, Lars Engelholm and Christoffer Nielsen from The Finsen Laboratory, had just recently published proof-of-concept for uPARAP-directed ADCs, where a first-generation, anti-uPARAP ADC was shown to effectively mediate a curative outcome in a CDX model. Ensuring that these findings were investigated further by creating a spin-out company for this purpose, was a natural next step

Join our ambitious team

Please reach out to us if you are interested in joining our international team of highly experienced cancer researchers and drug developers. Do you have relevant expertise and are attracted by a science-, value- and performance driven work environment? Then check out the careers section